Suppr超能文献

与钠-葡萄糖协同转运蛋白2抑制剂相关的正常血糖性糖尿病酮症酸中毒延迟诊断所致的危及生命并发症:2例报告

Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.

作者信息

Goto Shunsaku, Ishikawa Jun-Ya, Idei Masafumi, Iwabuchi Masahiro, Namekawa Motoki, Nomura Takeshi

机构信息

Department of Anesthesiology, Tokyo Women's Medical University, Tokyo, Japan.

Department of Intensive Care Medicine, Tokyo Women's Medical University, Tokyo, Japan.

出版信息

Am J Case Rep. 2021 Mar 16;22:e929773. doi: 10.12659/AJCR.929773.

Abstract

BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely used owing to their effective glycemic control and protective effects against heart and kidney failure. Euglycemic diabetic ketoacidosis (eu-DKA) is a complication of treatment with SGLT2is. Eu-DKA often leads to delayed diagnosis and results in life-threatening complications. We report 2 critical cases of SGLT2i-associated eu-DKA. CASE REPORT Case 1 was 52-year-old woman with unstable angina scheduled for elective coronary artery bypass grafting surgery. Preoperatively, she underwent tooth extraction which led to poor food intake because of pain. Three days before surgery, the patient had SGLT2i-associated eu-DKA and myocardial infraction, requiring percutaneous coronary intervention and peripheral venoarterial extracorporeal membrane oxygenation. The patient had taken SGLT2i until the morning of admission to the intensive care unit. Case 2 was a 76-year-old woman experiencing SGLT2i-associated eu-DKA and sinus arrest, necessitating a temporary pacemaker, followed by elective gastrojejunal bypass surgery. The SGLT2i was discontinued the day before surgery. On day 3 following surgery, the patient's metabolic acidosis improved, and sinus arrest resolved. CONCLUSIONS Precipitating factors of eu-DKA (caloric restriction and surgical stress) and delay in diagnosis because of a lack of evidence of hyperglycemia could contribute to the development and worsening of life-threatening complications. This reiterates the importance of reviewing ongoing medications of patients with diabetes and considering eu-DKA as a differential diagnosis for patients with high anion gap metabolic acidosis to ensure early intervention. SGLT2i-associated DKA likely develops perioperatively; therefore, clinicians should pay attention to the discontinuation period of SGLT2i before any surgical intervention.

摘要

背景

钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)因其有效的血糖控制及对心力衰竭和肾衰竭的保护作用而被广泛应用。正常血糖性糖尿病酮症酸中毒(eu-DKA)是SGLT2i治疗的一种并发症。eu-DKA常导致诊断延迟,并引发危及生命的并发症。我们报告2例SGLT2i相关eu-DKA的危急病例。病例报告:病例1为一名52岁患有不稳定型心绞痛的女性,计划行择期冠状动脉旁路移植术。术前,她接受了拔牙,因疼痛导致进食不佳。手术前3天,该患者发生了SGLT2i相关eu-DKA和心肌梗死,需要进行经皮冠状动脉介入治疗及外周静脉-动脉体外膜肺氧合。该患者在入住重症监护病房的当天早晨仍在服用SGLT2i。病例2为一名76岁女性,发生了SGLT2i相关eu-DKA和窦性停搏,需要植入临时起搏器,随后行择期胃空肠旁路手术。SGLT2i在手术前一天停用。术后第3天,患者的代谢性酸中毒改善,窦性停搏消失。结论:eu-DKA的诱发因素(热量限制和手术应激)以及因缺乏高血糖证据导致的诊断延迟可能促使危及生命的并发症发生和恶化。这再次强调了审查糖尿病患者正在服用的药物以及将eu-DKA作为高阴离子间隙代谢性酸中毒患者鉴别诊断的重要性,以确保早期干预。SGLT2i相关DKA可能在围手术期发生;因此,临床医生在任何手术干预前应注意SGLT2i的停用时间。

相似文献

引用本文的文献

本文引用的文献

2
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
3
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
10
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验